New technologies for the inactivation of infectious pathogens in cellular blood components and the development of platelet substitutes.
Despite the increased safety of blood components, achieved through improved donor selection and testing, transfusion recipients remain at risk of transfusion-associated diseases. Transfusion of cellular blood components has been implicated in transmission of viral, bacterial and protozoan diseases. While it is commonly recognized that hepatitis B virus (HBV), hepatitis C virus (HCV), cytomegalovirus (CMV), and retroviruses, such as human immunodeficiency virus (HIV) and the human lymphotrophic viruses (HTLV), can be transmitted through cellular components, other pathogens are emerging as potentially significant transfusion-associated infectious agents. For example, transmission of protozoan infections due to trypanosomes and Babesia have been reported. In addition to viral and protozoan infectious agents, cases of bacterial contamination of platelet and red cell concentrates continue to be reported and may be an under-reported transfusion complication. More importantly, new infectious agents continue to enter the donor population, and there is an inherent time delay before the new pathogens are definitively identified and new tests implemented in order to maintain consistent safety of the blood supply. The paradigm for this problem is the HIV pandemic. During the past decade a number of methods for inactivating infectious pathogens in platelet concentrates have been investigated as a strategy to improve the safety of platelet transfusion therapy. One method of treating platelet concentrates to inactive pathogens has now reached the advanced clinical trial phase in the United States and Europe. Similar efforts with a new class of compounds are underway for red cell concentrates, and two of these are in early phase trials. In addition to studies with allogeneic platelets and red cells, a number of laboratories have described methods for developing platelet substitutes or modified platelets to avoid the use of traditional platelet concentrates as a means to improve safety.
Corash
L
L
Cerus Corporation and the Department of Laboratory Medicine, University of California, San Francisco, USA.
D000890:Anti-Infective Agents; D001424:Bacterial Infections / Q000517:prevention & control / Q000635:transmission; D016913:Blood Component Transfusion; D001782:Blood Donors; D004912:Erythrocytes; D006401:Hematologic Agents; D006801:Humans; D007239:Infections / Q000635:transmission*; D017319:Photosensitizing Agents; D017713:Platelet Transfusion; D011528:Protozoan Infections / Q000517:prevention & control / Q000635:transmission; D014466:Ultraviolet Rays; D014777:Virus Diseases / Q000517:prevention & control / Q000635:transmission
D000890:Anti-Infective Agents; D006401:Hematologic Agents; D017319:Photosensitizing Agents